Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer

Minerva Urologica e Nefrologica

Volumn 60, Issue 4, 2008, Pages 217-235

  Herman, M P ^a   Svatek, R S ^b   Lotan, Y ^c   Karakiewizc, P I ^d   Shariat, S F ^c,e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biological markers; Carcinoma, transitional cell; Cystoscopy; Prognosis; Urinary bladder neoplasms

Indexed keywords

BIOLOGICAL MARKER; HYALURONIC ACID; HYALURONIDASE; MICROSATELLITE DNA; NUCLEAR MATRIX PROTEIN 22; SURVIVIN; TELOMERASE;

BLADDER CANCER; BLOOD GROUP LEWIS SYSTEM; CANCER DIAGNOSIS; CYSTOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; HUMAN; REVIEW; SENSITIVITY ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD15; CARCINOMA, TRANSITIONAL CELL; CYSTEINE PROTEINASE INHIBITORS; CYSTOSCOPY; FAS LIGAND PROTEIN; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; POPULATION SURVEILLANCE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 57649126208     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. 2007. CA Cancer J Clin 2007;57:43-66.
2. Prout GR, Jr., Barton BA, Griffin PP, Friedell GH. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group. J Urol 1992;148:1413-9.
3. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145:45-50.
4. van der Poel HG, Debruyne FM. Can biological markers replace cystoscopy? An update. Curr Opin Urol 2001;11:503-9.
5. Herr HW. The natural history of a T1 bladder cancer: life-long tumour diathesis. BJU Int 1999;84:1102-3.
6. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-8.
7. Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol 2003;170:226-9.
8. Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7.
9. Svatek RS, Lee D, Lotan Y. Correlation of office-based cystoscopy and cytology with histologic diagnosis: how good is the reference standard? Urology 2005;66:65-8.
10. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001;165:1121-3.
11. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18; discussion 18.
12. Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006;97:997-1001.
13. Lokeshwar V, Soloway M. Current Bladder Tumor Tests: Does Their Projected Utility Fulfill Clinical Necessity? Journal of Urology 2001;165:1067-77.
14. Svatek RS, Sagalowsky AI, Lotan Y. Economic impact of screening for bladder cancer using bladder tumor markers: a decision analysis. Urol Oncol 2006;24:338-43.
15. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer 2006;107:982-90.
16. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: A comparative study of point of care tests. J Urol 1997;158:2098-101.
17. Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511-20.
18. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-80.
19. Takashi M, Schenck U, Kissel K, Leyh H, Treiber U. Use of diagnostic categories in urinary cytology in comparison with the bladder tumour antigen (BTA) test in bladder cancer patients. Int Urol Nephrol 1999;31:189-96.
20. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
21. Gutierrez Banos JL, Martin Garcia B, Hernandez Rodriguez R, Portillo Martin JA, Correas Gomez MA, del Valle Schaan JI et al. [Usefulness of BTA Stat test (Bard) in the diagnosis of bladder cancer. Preliminary results and comparison with cytology and cystoscopy]. Arch Esp Urol 1998;51:778-82.
22. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
23. Leyh H, Mazeman E. Bard BTA Test Compared with Voided Urine Cytology in the Diagnosis of Recurrent Bladder Cancer. Eur Urol 1997;32:425-8.
24. Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F et al. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999;35:52-6.
25. Nasuti JF, Gomella LG, Ismial M, Bibbo M. Utility of the BTA stat test kit for bladder cancer screening. Diagn Cytopathol 1999;21:27-9.
26. Oge O, Kozaci D, Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol 2002;167:1318-9; discussion 9-20.
27. Raitanen MP. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies. World J Urol 2008;26:45-50.
28. Malkowicz SB. The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer. Urol Clin North Am 2000;27:63-73.
29. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45:472-7.
30. Mahnert B, Tauber S, Kriegmair M, Schmitt UM, Hasholzner U, Reiter W et al. BTA-TRAK - a useful diagnostic tool in urinary bladder cancer? Anticancer Res 1999;19:2615-9.
31. Irani J, Desgrandchamps F, Millet C, Toubert ME, Bon D, Aubert J et al. BTA stat and BTA TRAK: A comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999;35:89-92.
32. Heicappell R, Wettig IC, Schostak M, Muller M, Steiner U, Sauter T et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of the urinary bladder. Eur Urol 1999;35:81-7.
33. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997;50:882-7.
34. Abbate I, D'Introno A, Cardo G, Marano A, Addabbo L, Musci M et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 1998;18:3803-5.
35. Babjuk M, Soukup V, Pesl M, Kostirova M, Drncova E, Smolova H et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 2008;71:718-22.
36. Tsui KH, Chen SM, Wang TM, Juang HH, Chen CL, Sun GH et al. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl 2007;9:711-5.
37. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: Immunocyt. Canad J Urol 1997;4:400.
38. Greene KL, Berry A, Konety BR. Diagnostic Utility of the ImmunoCyt/uCyt+ Test in Bladder Cancer. Rev Urol 2006;8:190-7.
39. Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001;35:280-2.
40. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9.
41. Vriesema JLJ, Atsma F, Kiemeney LALM, Peelen WP, Witjes JA, Schalken JA. Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001;58:367-71.
42. Mian C, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Lusuardi L et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology 2003;14:338-42.
43. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003;169:921-4.
44. Gordon JN, Shu WP, Schlussel RN, Droller MJ, Liu BCS. Altered extracellular matrices influence cellular processes and nuclear matrix organisations of overlying human bladder urothelial cells. Cancer Res 1993;53:4971-7.
45. Berezney R, Coffey DS. Identification of a nuclear protein matrix. Biochem Biophys Res Commun 1974;60:1410-7.
46. Pardoll DM, Vogelstein B, Coffey DS. A fixed site of DNA replication in eukaryotic cells. Cell 1980;19:
47. Compton DA, Cleveland DW. NuMA is required for the proper completion of mitosis. J Cell Biol 1993;120:947-57.
48. Shelfo SW, Soloway MS. The role of nuclear matrix protein 22 in the detection of persistent or recurrent transitional-cell cancer of the bladder. World J Urol 1997;15:107-11.
49. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-94.
50. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 1999;6:173-7.
51. Hughes JH, Katz RL, Rodriguez-Villanueva J, Kidd L, Dinney C, Grossman HB et al. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 1999;20:285-90.
52. Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999;19:2621-3.
53. Del Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol 1999;35:93-7.
54. Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998;52:793-6.
55. Witjes JA, van der Poel HG, van Balken MR, Debruyne FM, Schalken JA. Urinary NMP22 and karyometry in the diagnosis and follow-up of patients with superficial bladder cancer. Eur Urol 1998;33:387-91.
56. Stampfer D, Carpinito G, Rodriguez-Villanueva J, Willsey L, Dinney C, Grossman H et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998;159:394-8.
57. Soloway MS, Briggman V, Carpinito GA, Chodak GW, Church PA, Lamm DL et al. Use of new tumor marker, urinary NMP22, in detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-7.
58. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A et al. Screening and Monitoring for Bladder Cancer: Refining the Use of NMP22. J Urol 2001;166:75-8.
59. Mansoor I, Calam RR, Al-Khafaji B. Role of urinary NMP-22 combined with urine cytology in follow-up surveillance of recurring superficial bladder urothelial carcinoma. Anal Quant Cytol Histol 2008;30:25-32.
60. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176:919-26.
61. Shariat SF, Casella R, Wians FH, Jr., Ashfaq R, Balko J, Sulser T et al. Risk stratification for bladder tumor recur rence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004;45:304-13; author reply 13.
62. Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005;173:1518-25.
63. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
64. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295:299-305.
65. Lotan Y, Shariat SF. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008;101:1362-7.
66. Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 2003;62:1134-8
67. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur Urol 2007;51:1275-80; discussion 80.
68. Halling KC. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507-19.
69. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5.
70. Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H. Are false-positive urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Fur Urol 2003;43:146-50; discussion 50-1.
71. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167:2001-6.
72. Hajdinjak T. UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol 2008;
73. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 2007;111:517-24.
74. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstien Y et al. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 2005;66:1354-9.
75. Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky Al, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. J Urol 2008;179:2164-9.
76. Bergman J, Reznichek RC, Rajfer J. Surveillance of patients with bladder carcinoma using fluorescent insitu hybridization on bladder washings. BJU Int 2008;101:26-9.
77. Gofrit ON, Zorn KC, Silvestre J, Shalhav AL, Zagaja GP, Msezane LP et al. The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol 2008;26:246-9.
78. Yoder BJ, Skacel M, Hedgepeth R, Bahineau D, Ulchaker JC, Liou IS et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295-301.
79. Heicappell R, Schostack M, Muller M, Miller K. Evaluation of urinary bladder cancer antigen as a marker for diagnosis of transitional cell carcinoma of the urinary bladder. Scand J Clin Lab Invest 2000;60:275-82.
80. Mian C, Lodde M, Haitel A, Egarter Vigl E, Marberger M, Pycha A. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology 2000;56:228-31.
81. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Woodman AC. The Early Detection and Diagnosis of Bladder Cancer: A Critical Review of the Options. European Urology 2001;39:619-33.
82. Babjuk M, Kostirova M, Mudra K, Pecher S, Smolova H, Pecen L et al. Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol 2002;41:34-9.
83. Hakenberg OW, Fuessel S, Richter K, Froehner M, Oehlschlaeger S, Rathert P et al. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma. Urology 2004;64:1121-6.
84. Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol 2005;174:64-8.
85. Myers-Irvin JM, Van Le TS, Getzenberg RH. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Res 2005;65:7145-50.
86. Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM et al. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 2000;6:2618-25.
87. Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH. Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res 2004;10:1384-91.
88. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, Getzenberg RH. Highly specific urine-based marker of bladder cancer. Urology 2005;66:1256-60.
89. Konety BR, Nguyen TS, Brenes G, Sholder A, Lewis N, Bastacky S et al. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000;164:634-9.
90. Knudson W. Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol 1996;148:1721-6.
91. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997;57:773-7.
92. Lokeshwar VB, Block NL. HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade. Urol Clin North Am 2000;27:53-61.
93. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res 1997;57:778-83.
94. Hautmann SH, Lokeshwar VB, Schroeder GL, Civantos F, Duncan RC, Gnann R et al. Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol 2001;165:2068-74.
95. Lokeshwar VB, Schroeder GL, Selzer MG, Hautmann SH, Posey JT, Duncan RC et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer 2002;95:61-72.
96. Hautmann S, Toma M, Lorenzo Gomez MF, Friedrich MG, Jaekel T, Michl U et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol 2004;46:466-71.
97. Decenzo JM, Howard P, Irish CE. Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma. J Urol 1975;114:874-8.
98. Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995;46:173-7.
99. Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998;159:389-92; discussion 93.
100. Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002;168:470-4.
101. van Rhijn BW, Lurkin I, Kirkels WJ, van der Kwast TH, Zwarthoff EC. Microsatellite analysis - DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001;92:768-75.
102. Czerniak B, Chaturvedi V, Li L, Hodges S, Johnston D, Roy JY et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999;18:1185-96.
103. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994;54:531-8.
104. von Knobloch R, Hegele A, Brandt H, Olbert P, Heidenreich A, Hofmann R. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer 2001;94:67-72.
105. van der Aa MN, Zwarthoff EC, Steyerberg EW, Boogaard MW, Nijsen Y, van der Keur KA et al. Microsatellite Analysis of Voided-Urine Samples for Surveillence of Low-Grade Non-Muscle-Invasive Urothelial Carcinoma: Feasibility and Clinical Utility in a Prospective Multicenter Study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer Trial [CEFUB]). Eur Urol 2008;
106. van der Poel HG, van Balken MR, Schamhart DH, Peelen P, de Reijke T, Debruyne FM et al. Bladder wash cytology, quantitative cytology, and the qualitative BTA test in patients with superficial bladder cancer. Urology 1998;51:44-50.
107. Gregoire M, Fradet Y, Meyer F, Tetu B, Bois R, Bedard G et al. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid Flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol 1997;157:1660-4.
108. Cajulis RS, Haines GK, 3rd, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995;13:214-23; discussion 24.
109. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI et al. Soluble Fas - a promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106:1701-7.
110. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9.
111. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol 2008;26:59-65.
112. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Alterieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
113. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626-30.
114. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50:1425-8.
115. Weikert S, Christoph F, Schrader M, Krause H, Miller K, Muller M. Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer 2005;116:100-4.
116. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. Jama 2001;285:324-8.
117. Greider CW. Telomere length regulation. Annu Rev Biochem 1996;65:337-65.
118. Blackburn EH. Telomeres and their synthesis. Science 1990;249:489-90.
119. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-73.
120. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989;59:521-9.
121. Ito H, Kyo S, Kanaya T, Takakura M, Inoue M, Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin Cancer Res 1998;4:1603-8.
122. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
123. De Kok JB, Schalken JA, Aalders TW, Ruers TJ, Willems HL, Swinkels DW. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer 2000;87:217-20.
124. Melissourgos N, Kastrinakis NG, Davilas I, Foukas P, Farmakis A, Lykourinas M. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology 2003;62:362-7.
125. Wu X, Kakehi Y, Takahashi T, Habuchi T, Ogawa O. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence. Int J Urol 2000;7:210-7.
126. Cheng CW, Chueh SC, Chern HD. Diagnosis of bladder cancer using telomerase activity in voided urine. J Formos Med Assoc 2000;99:920-5.
127. Cassel A, Rahat MA, Lahat N, Lindenfield N, Mecz Y, Stein A. Telomerase activity and cytokeratin 20 as markers for the detection and followup of transitional cell carcinoma: an unfulfilled promise. J Urol 2001;166: 841-4.
128. Kavaler E, Landman J, Chang Y, Droller MJ, Liu BC. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998;82:708-14.
129. Lee DH, Yang SC, Hong SJ, Chung BH, Kim IY. Telomerase: a potential marker of bladder transitional cell carcinoma in bladder washes. Clin Cancer Res 1998;4:535-8.
130. Dalbagni G, Han W, Zhang ZF, Cordon-Cardo C, Saigo P, Fair WR et al. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. Clin Cancer Res 1997;3:1593-8.
131. Yokota K, Kanda K, Inoue Y, Kanayama H, Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Urol 1998;82:727-32.
132. Mayfield MP, Shah T, Flannigan GM, Hamilton Stewart PA, Bibby MC. Telomerase activity in malignant and benign bladder conditions. Int J Mol Med 1998;1:835-40.
133. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998;4:1949-54.
134. Lee MY, Tsou MH, Cheng MH, Chang DS, Yang AL, Ko JS. Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma. World J Urol 2000;18:401-5.
135. Weikert S, Krause H, Wolff I, Christoph F, Schrader M, Emrich T et al. Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer. Int J Cancer 2005;117:274-80.
136. Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A et al. Relevance of urine telomerase in the diagnosis of bladder cancer. Jama 2005;294:2052-6.
137. Soloway MS. Editorial: Bladder Tumor Markers, Intravesical Therapy and Systemic Chemotherapy. Journal of Urology 2001;166:488-9.
138. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol 2007;177:1277-82; discussion 82.
139. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Fur Urol 2007;52:1601-9.